The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Deferasirox-induced renal impairment in children: an increasing concern for pediatricians
Abstract
Background Deferasirox (DFX) is an oral iron chelator with an established dose-dependent efficacy in transfusion-related iron overload. Whereas emerging long-term data confirm the safety of the drug, with transient moderate elevation of serum creatinine level, several authors have reported renal tubular dysfunction. The aim of this study was to evaluate tubular and glomerular function before and after the initiation of DFX therapy in a pediatric patient population. Methods Ten children (4 girls, mean age 12.4 ± 3.9 years) enrolled in a routine blood transfusion program were treated with 24.8 ± 9.6 mg/kg per day of DFX, and renal function was assessed before and 17.2 ± 8.9 months after the initiation of DFX therapy. Results Prior to treatment with DFX, all patients had a normal glomerular function rate (GFR) (125 ± 15 ml/min per 1.73 m(2)) and normal tubular function. Following the initiation of DFX therapy, the GFR decreased by approximately 20 % with one patient with a GFR of Conclusions Renal toxicity is a frequent adverse event of DFX treatment, presenting as both glomerular and proximal dysfunction. A routine renal assessment is therefore required to prevent chronic kidney disease that may result from prolonged tubular injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“due to potential side‐effects of renal toxicity after repeated treatment, it is not ethically easy to apply this to humans who have been already exposed to asbestos.26, 27”
From Dual preventive benefits of iron elimination by desferal in asbestos‐induced mesothelial carcinogenesis (2016) · cites this paper as [27]
Citations
Cites
A formula to estimate the approximate surface area if height and weight be known. 1916.
Bois, D. D., & Bois, E. F. D. (1989) · PubMed · Cited by 5,314
New Equations to Estimate GFR in Children with CKD
Schwartz, G. J., Mun[Combining Tilde]oz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008030287 · Cited by 3,777
Cappellini, M. D. (2006) · Blood · doi:10.1182/blood-2005-08-3430 · Cited by 717
Nisbet-Brown, E., Olivieri, N. F., Giardina, P. J., Grady, R. W., Neufeld, E. J., Séchaud, R., Krebs-Brown, A. J., Anderson, J. R., Alberti, D., Sizer, K. C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13309-0 · Cited by 328
Vichinsky, E., Onyekwere, O., Porter, J., Swerdlow, P., Eckman, J., Lane, P., Files, B., Hassell, K., Kelly, P., Wilson, F., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06455.x · Cited by 271
Piga, A. G., Galanello, R., Forni, G. L., Cappellini, M. D., Origa, R., Zappu, A., Donato, G., Bordone, E., Lavagetto, A., Zanaboni, L., et al. (2006) · PubMed · Cited by 264
Cappellini, M. D., Bejaoui, M., Agaoglu, L., Canatan, D., Capra, M., Cohen, A., Drelichman, G., Economou, M., Fattoum, S., Kattamis, A., et al. (2011) · Blood · doi:10.1182/blood-2010-11-316646 · Cited by 222
Angelucci, E., Barosi, G., Camaschella, C., Cappellini, M. D., Cazzola, M., Galanello, R., Marchetti, M., Piga, A., & Tura, S. (2008) · Haematologica · doi:10.3324/haematol.12413 · Cited by 203
Delea, T. E., Edelsberg, J., Sofrygin, O., Thomas, S. K., Baladi, J., Phatak, P. D., & Coates, T. D. (2007) · Transfusion · doi:10.1111/j.1537-2995.2007.01416.x · Cited by 180
Development of Tridentate Iron Chelators: From Desferrithiocin to ICL670
Nick, H., Acklin, P., Lattmann, R., Buehlmayer, P., Hauffe, S., Schupp, J., & Alberti, D. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033457610 · Cited by 168
Taher, A. T., El-Beshlawy, A. M., Elalfy, M. S., Zir, K. A., Daar, S., Habr, D., Kriemler‐Krahn, U., Hmissi, A., & Al‐Jefri, A. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01228.x · Cited by 147
Galanello, R., Piga, A. G., Forni, G. L., Bertrand, Y., Foschini, M. L., Bordone, E., Leoni, G., Lavagetto, A., Zappu, A., Longo, F., et al. (2006) · PubMed · Cited by 138
Renal function in pediatric patients with β-thalassemia major
Aldudak, B., Bayazıt, A. K., Noyan, A., Özel, A., Anarat, A., Şaşmaz, İ., Kılınç, Y., Gali, E., Anarat, R., & Dikmen, N. (2000) · Pediatric Nephrology · doi:10.1007/s004670000434 · Cited by 110
Renal dysfunction in patients with thalassaemia
Quinn, C. T., Johnson, V. L., Kim, H., Trachtenberg, F. L., Vogiatzi, M. G., Kwiatkowski, J. L., Neufeld, E. J., Fung, E. B., Oliveri, N. F., Kirby-Allen, M. A., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08477.x · Cited by 109
Concepts and goals in the management of transfusional iron overload
Porter, J. B. (2007) · American Journal of Hematology · doi:10.1002/ajh.21100 · Cited by 100
Long-term efficacy and safety of deferasirox
Cappellini, M. D. (2008) · Blood Reviews · doi:10.1016/s0268-960x(08)70007-9 · Cited by 90
Koliakos, G., Papachristou, F., Koussi, A., Perifanis, V., Tsatra, I., Souliou, E., & Athanasiou, M. (2003) · Clinical & Laboratory Haematology · doi:10.1046/j.1365-2257.2003.00507.x · Cited by 80
Economou, M. P., Printza, N., Teli, Α., Tzimouli, V., Tsatra, I., Papachristou, F., & Athanassiou‐Metaxa, M. (2010) · Acta Haematologica · doi:10.1159/000287238 · Cited by 78
Acute Changes in Renal Function Associated With Deferoxamine Therapy
Koren, G. (1989) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1989.02150210113029 · Cited by 78
Renal function in children with β-thalassemia major and thalassemia intermedia
Smolkin, V., Halevy, R., Levin, C., Mines, M., Sakran, W., Ilia, K., & Koren, A. (2008) · Pediatric Nephrology · doi:10.1007/s00467-008-0897-8 · Cited by 77
Fanconi Syndrome Due to Deferasirox
Rafat, C., Fakhouri, F., Ribeil, J., Delarue, R., & Quintrec, M. L. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.03.013 · Cited by 76
Renal tubular function in β-thalassemia
Sumboonnanonda, A., Malasit, P., Tanphaichitr, V. S., Ong-Ajyooth, S., Sunthornchart, S., Pattanakitsakul, S., Petrarat, S., Assateerawatt, A., & Vongjirad, A. (1998) · Pediatric Nephrology · doi:10.1007/s004670050453 · Cited by 76
Acute renal failure and Fanconi syndrome due to deferasirox
Grangé, S., Bertrand, D., Guerrot, D., Eas, F., & Godin, M. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq224 · Cited by 65
Deferasirox for Transfusion-Related Iron Overload: A Clinical Review
Lindsey, W. T., & Olin, B. R. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.10.015 · Cited by 64
Acquired Proximal Renal Tubular Dysfunction in β-Thalassemia Patients Treated With Deferasirox
Yacobovich, J., Stark, P., Barzilai‐Birenbaum, S., Krause, I., Pazgal, I., Yaniv, I., & Tamary, H. (2010) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181ec0c38 · Cited by 58
Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy
Cianciulli, P., Sollecito, D., Sorrentino, F., Forte, L., Gilardi, E., Massa, A., Papa, G. F. S., & Carta, S. (1994) · Kidney International · doi:10.1038/ki.1994.295 · Cited by 56
Reversible Fanconi syndrome in a pediatric patient on deferasirox
Rheault, M. N., Bechtel, H., Neglia, J. P., & Kashtan, C. E. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22711 · Cited by 56
Iron loading and its clinical implications
Hershko, C. (2007) · American Journal of Hematology · doi:10.1002/ajh.21070 · Cited by 45
Acute interstitial nephritis due to deferasirox: a case report
Brosnahan, G., Gökden, N., & Swaminathan, S. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn423 · Cited by 41
Fanconi syndrome in a patient with β‐thalassemia major after using deferasirox for 27 months
Wei, H., Yang, C., Cheng, C., & Lo, F. (2010) · Transfusion · doi:10.1111/j.1537-2995.2010.02939.x · Cited by 34
Adaptation of an enzymatic polyfructosan assay to clinical practice
Dubourg, L. D., Hadj‐Aïssa, A., & Ferrier, B. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.06.016 · Cited by 32
Self-citationHyperchloremic Metabolic Acidosis Due to Deferasirox in a Patient with Beta Thalassemia Major
Papadopoulos, N., Aresti, V., Aloizos, G., Tapinis, P., & Kikilas, A. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m440 · Cited by 29
Deferasirox treatment may be associated with reversible renal Fanconi syndrome
Even‐Or, E., Becker‐Cohen, R., & Miskin, H. (2009) · American Journal of Hematology · doi:10.1002/ajh.21588 · Cited by 28
Cystatin C levels in patients with β-thalassemia during deferasirox treatment
Papassotiriou, I., Margeli, A. P., Hantzi, E., Delaporta, P., Sergounioti, A., Goussetis, E., Ladis, V., & Kattamis, A. (2010) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2010.01.001 · Cited by 25
Jl, A., Deschamps, J., & Gueguen, R. (1981) · PubMed · Cited by 24
Renal Fanconi Syndrome Secondary to Deferasirox: Where There Is Smoke There Is Fire
Baum, M. G. (2010) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181ec0c4d · Cited by 20
YEW, C. T., Talaulikar, G. S., Falk, M. C., Clayton, P. A., D’Rozario, J., & Brown, M. T. (2010) · Nephrology · doi:10.1111/j.1440-1797.2009.01183.x · Cited by 15
Desferrithiocin Analogues and Nephrotoxicity
Bergeron, R. J., Wiegand, J., McManis, J. S., Bharti, N., & Singh, S. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8003398 · Cited by 13
Cappellini, M. D., Galanello, R., Piga, A. G., Cohen, A. R., Kattamis, A., Aydınok, Y., Williamson, P., Rojkjaer, L. P., & Porter, J. B. (2008) · Blood · doi:10.1182/blood.v112.11.5411.5411 · Cited by 12
Piga, A. G., Forni, G. L., Kattamis, A., KATTAMIS, C. A., Aydınok, Y., Rodriguez, M., Rojkjaer, L. P., & Galanello, R. (2008) · Blood · doi:10.1182/blood.v112.11.3883.3883 · Cited by 10
Les médicaments dangereux pour le rein
Ghuysen, M.-S. (2005) · Archives de Pédiatrie · doi:10.1016/j.arcped.2005.04.059 · Cited by 3
Cited by
Nagai, H., Okazaki, Y., Chew, S. H., Misawa, N., Yasui, H., & Toyokuni, S. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0244 · Cited by 39
Jiang, L., Chew, S., Nakamura, K., Ohara, Y., Akatsuka, S., & Toyokuni, S. (2016) · Cancer Science · doi:10.1111/cas.12947 · Cited by 19
Metadata
- Authors
- Dubourg, L., Laurain, C., Ranchin, B., Pondarré, C., Hadj-Aïssa, A., Sigaudo-Roussel, D., & Cochat, P.
- Venue
- Pediatric Nephrology
- Published
- 2012-04-24
- Volume
- 27
- Issue
- 11
- Pages
- 2115-2122
- ISSN
- 0931-041X
- 1432-198X
- Cited by
- 39
- References
- 41
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.